Phase II trial of pemetrexed in patients with selected stage IIIB/IV bronchioloalveolar carcinoma

Clinical Lung Cancer

Volumn 8, Issue 3, 2006, Pages 220-222

  Ho, Cheryl ^a   Ross, Helen ^b   Davies, Angela ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b PROVIDENCE PORTLAND MEDICAL CENTER   (United States)

Author keywords

Antifolate; Epidermal growth factor receptor; Lepidic growth; folate receptor

Indexed keywords

CYANOCOBALAMIN; DEXAMETHASONE; FOLIC ACID; PEMETREXED;

ADULT; ADVANCED CANCER; ARTICLE; CANCER STAGING; CLINICAL TRIAL; DIARRHEA; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG ERUPTION; FATIGUE; HUMAN; LUNG ALVEOLUS CELL CARCINOMA; MAJOR CLINICAL STUDY; NAUSEA; OVERALL SURVIVAL; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; STOMATITIS; VITAMIN SUPPLEMENTATION; VOMITING;

EID: 33845394697     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2006.n.052     Document Type: Article

References (15)

1. Read WL, Page NC, Tierney RM, et al. The epidemiology of bronchioloalveolar carcinoma over the past two decades: analysis of the SEER database. Lung Cancer 2004; 45:137-142.
2. Dumont P, Gasser B, Rouge C, et al. Bronchoalveolar carcinoma: histopathologic study of evolution in a series of 105 surgically treated patients. Chest 1998; 113:391-395.
3. Breathnach OS, Ishibe N, Williams J, et al. Clinical features of patients with stage IIIB and IV bronchioloalveolar carcinoma of the lung. Cancer 1999; 86:1165-1173.
4. Giaccone G, Kris MG, Davies A, et al. Consensus Conference on Systemic Therapy in Bronchioloalveolar Carcinoma. J Thorac Oncol. In press.
5. West HL, Crowley JJ, Vance RB, et al. Advanced bronchioloalveolar carcinoma: a phase II trial of paclitaxel by 96-hour infusion (SWOG 9714): a Southwest Oncology Group study. Ann Oncol 2005; 16:1076-1080.
6. Scagliotti GV, Smit E, Bosquee L, et al. A phase II study of paclitaxel in advanced bronchioloalveolar carcinoma (EORTC trial 08956). Lung Cancer 2005; 50:91-96.
7. West H, Franklin WA, McCoy J, et al. Gefitinib (ZD1839) therapy for advanced bronchioloalveolar lung cancer: Southwest Oncology Group Study S0126. J Clin Oncol 2006; 24:1807-1813.
8. Hirsch FR, Varella-Garcia M, McCoy J, et al. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group study. J Clin Oncol 2005; 23:6838-6845.
9. Kris MG, Sandler A, Miller V, et al. Cigarette smoking history predicts sensitivity to erlotinib: results of a phase II trial in patients with bronchioloalveolar carcinoma (BAC). J Clin Oncol 2004; 22:7062.
10. Tracy S JP, Johnson BE. Sensitivity of bronchioloalveolar carcinoma and adenocarcinoma of the lung to pemetrexed. Presented at: Europan Organization for Research and Treatment of Cancer Group Annual Meeting; April 21-23, 2004; Brussels, Belgium.
11. Theti DS, Jackman AL, Jhaveri MS, et al. The role of alpha-folate receptor-mediated transport in the antitumor activity of antifolate drugs. Clin Cancer Res 2004; 10:1080-1089.
12. Jhaveri MS, Rait AS, Chung KN, et al. Antisense oligonucleotides targeted to the human alpha folate receptor inhibit breast cancer cell growth and sensitize the cells to doxorubicin treatment. Mol Cancer Ther 2004; 3:1505-1512.
13. Rosell R, Taron M, Sanchez JM, et al. The promise of pharmacogenomics: gemcitabine and pemetrexed. Oncology (Williston Park) 2004; 18:70-76.
14. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22:1589-1597.
15. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21:2636-2644.